Comparing Jakafi vs Ruxolitinib
| Jakafi | Ruxolitinib |
|
|---|
| Jakafi (ruxolitinib) | Ruxolitinib |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Myelofibrosis, Polycythemia Vera, Graft-versus-host disease, Myeloproliferative Disorders. Jakafi may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myelofibrosis, Polycythemia Vera, Graft-versus-host disease, Myeloproliferative Disorders. ruxolitinib may also be used for purposes not listed in this medication guide. |
Related suggestions Polycythemia Vera
Myelofibrosis
Graft-versus-host disease
|
|||||||
| More about Jakafi (ruxolitinib) | More about Ruxolitinib | ||||||||
| Generic Status | |||||||||
|
No lower-cost generic available |
No lower-cost generic available |
||||||||
| Ratings & Reviews | |||||||||
|
Jakafi has an average rating of 6.2 out of 10 from a total of 18 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 28% reported a negative effect. |
Ruxolitinib has an average rating of 6.6 out of 10 from a total of 25 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 25% reported a negative effect. |
||||||||
| Drug Class | |||||||||
| Side Effects | |||||||||
|
Common side effects include:
See also: Jakafi side effects in more detail. |
Commonly reported side effects include:
See also: ruxolitinib side effects in more detail. |
||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Jakafi prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Form(s) Available | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Jakafi | ||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||||||||
|
5.8 hours |
5.8 hours |
||||||||
| CSA Schedule ** View glossary of terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 416 drugs are known to interact with Jakafi:
|
A total of 416 drugs are known to interact with ruxolitinib:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
November 16, 2011 |
November 16, 2011 |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.